Pichia Patents (Class 435/254.23)
-
Publication number: 20150023966Abstract: This disclosure relates to combination therapies comprising anti-Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.Type: ApplicationFiled: November 6, 2012Publication date: January 22, 2015Inventors: Antonio Digiandomenico, Paul Warrener, Charles Stover, Bret Sellman, Ralph Minter, SAndrine Guillard, Steven Rust, Mladen Tomich, Vignesh Venkatraman, Reena Varkey, Li Peng, Melissa Damschroder, Partha Chowdhury, Nazzareno Dimasi, Ryan Fleming, Binyam Bezabeh, Changshou Gao, Godfrey Rainney, Cuihua GAO
-
Publication number: 20150024439Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: ApplicationFiled: September 29, 2014Publication date: January 22, 2015Inventors: Kimberly Brown, Paul Harris, Elizabeth Zaretsky, Edward Re, Elena Vlasenko, Keith McFarland, Alfredo Lopez de Leon
-
Publication number: 20150017686Abstract: Disclosed are methods for reducing detectable mannosylation of N-linked and O-linked oligosaccharides in lower eukaryote host cells. In particular, recombinant lower eukaryote host cells are provided in which expression of the GDP-mannose transporter encoded by the Vanadate Resistant Glycosylation 4 (VRG4) gene has been disrupted. In general, the VRG4 gene is essential for cell viability; however, the present invention provides host cells that are viable when expression of the VRG4 gene therein has been disrupted. The host cells are capable of producing proteins or glycoproteins that have reduced or no detectable ?-linked mannose, ?-linked mannose or phosphomannose containing N- and/or O-glycans.Type: ApplicationFiled: February 13, 2013Publication date: January 15, 2015Inventor: Stephen R. Hamilton
-
Publication number: 20150017695Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize a variety of chiral compounds.Type: ApplicationFiled: September 30, 2014Publication date: January 15, 2015Inventors: Jack Liang, Stephane J. Jenne, Emily Mundorff, Charlene Ching, John M. Gruber, Anke Krebber, Gjalt W. Huisman
-
Publication number: 20150017178Abstract: The present invention pertains to novel antibodies capable of binding to CD26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing Graft-versus-Host Disease (GvHD), for use in treating Aplastic Anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation. Furthermore, the present invention provides pharmaceutical compositions comprising at least one antibody of the present invention, as well as provides a kit of parts.Type: ApplicationFiled: February 19, 2014Publication date: January 15, 2015Inventor: Antonio Francesco DI NARO
-
Publication number: 20150010973Abstract: The invention relates to fungal strains having at least one genetic modification which leads to a reduction of the activity of at least one fungal carboxylic acid transporter and to a method for producing or using said fungal strains.Type: ApplicationFiled: December 12, 2012Publication date: January 8, 2015Applicant: THYSSENKRUPP INDUSTRIAL SOLUTIONS AGInventors: Andreas Aurich, Martina Holz, Anne Kretzschmar, Christina Otto, Gerold Barth, Isabel Waengler, Roland Arno Müller
-
Publication number: 20150010943Abstract: The present invention relates to genetic modifications in eukaryotic host cells that have been transformed to express a xylose isomerase that confers on the host cell the ability to isomerize xylose to xylulose. These genetic modifications are aimed at improving the efficiency of xylose metabolism and include, e.g., reduction of nonspecific aldose reductase activity, increased xylulose kinase activity and increased flux of the pentose phosphate pathway. The modified host cells of the invention are suitable for the production of a wide variety of fermentation products, including ethanol, in fermentation processes in which a source of xylose or a source of xylose and glucose are used as carbon source.Type: ApplicationFiled: June 24, 2014Publication date: January 8, 2015Inventors: Aaron Adriaan WINKLER, Sipko Maarten KUYPER, Wilhelmus Theodorus Antonius Maria DE LAAT, Johannes Pieter VAN DIJKEN, Jacobus Thomas PRONK
-
Publication number: 20150010985Abstract: The present disclosure relates to host cells containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell. The present disclosure further relates to methods of increasing transport of cellodextrin into a cell, methods of increasing growth of a cell on a medium containing cellodextrin, methods of co-fermenting cellulose-derived and hemicellulose-derived sugars, and methods of making hydrocarbons or hydrocarbon derivatives by providing a host cell containing a recombinant polynucleotide encoding a polypeptide where the polypeptide transports cellodextrin into the cell.Type: ApplicationFiled: May 28, 2014Publication date: January 8, 2015Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, The Board of Trustees of the University of Illinois, BP CORPORATION NORTH AMERICA INC.Inventors: N. Louise GLASS, Chaoguang TIAN, William T. BEESON, IV, Huimin ZHAO, Jing DU, Jin Ho CHOI, James H. DOUDNA CATE, Jonathan M. GALAZKA, Suk-Jin HA, Yong-Su JIN, Soo Rin KIM, Sijin LI, Xiaomin YANG
-
Publication number: 20150011482Abstract: Nutritive proteins are provided. In some embodiments the nutritive proteins comprise a first polypeptide sequence comprising a fragment of a naturally-occurring nutritive protein. In some embodiments the fragment comprises at least one of a) an enhanced ratio of branch chain amino acid residues to total amino acid residues present in the nutritive protein; b) an enhanced ratio of leucine residues to total amino acid residues present in the nutritive protein; and c) an enhanced ratio of essential amino acid residues to total amino acid residues present in the nutritive protein.Type: ApplicationFiled: March 15, 2013Publication date: January 8, 2015Inventors: David Arthur Berry, Brett Adam Boghigian, Nathaniel W. Silver, Geoffrey von Maltzahn, Rajeev Chillakuru, Michael Hamill
-
Publication number: 20150004690Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.Type: ApplicationFiled: August 29, 2014Publication date: January 1, 2015Inventors: Corinne JOHN, Christian SCHAUB, Sabine WELLNITZ
-
Publication number: 20150007368Abstract: Provided are valencene synthase polypeptides, nucleic acid molecules encoding the valencene synthases, host cells containing the nucleic acids and methods for producing products whose production is catalyzed by the polypeptides. Also provided are methods for producing valencene and nootkatone.Type: ApplicationFiled: March 11, 2014Publication date: January 1, 2015Inventors: Dayal Saran, Grace Eunyoung Park
-
Publication number: 20150004137Abstract: The present invention relates to heterogeneous or artificially created forms of plant defensins, and to uses of such heterogenous or artificially created defensins including methods for preventing or treating proliferative diseases. Compositions for use as animal and human medicaments are also provided. The present invention also relates to associated methods, uses, systems and kits.Type: ApplicationFiled: October 19, 2012Publication date: January 1, 2015Applicant: BALMORAL AUSTRALIA PTY LTDInventors: Mark Darren Hulett, Ivan Ka Ho Poon
-
Publication number: 20150005231Abstract: An insulin analogue comprises a B-chain polypeptide incorporating a halogenated phenylalanine at position B24, B25 or B26. The halogenated phenylalanine may be ortho-monofluoro-phenylalanine, ortho-monobromo-phenylalanine, ortho-monochloro-phenylalanine, or para-monochloro-phenylalanine. The analogue may be of a mammalian insulin, such as human insulin. A nucleic acid encodes such an insulin analogue. The halogenated insulin analogues retain significant activity. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. Halogen substitution-based stabilization of insulin may enhance the treatment of diabetes mellitus in regions of the developing world lacking refrigeration.Type: ApplicationFiled: September 3, 2014Publication date: January 1, 2015Inventor: Michael WEISS
-
Publication number: 20140377802Abstract: Novel promoters which are derived from P. pastoris pastoris which are inducible or repressible under specific growth conditions are provided. These promoters are useful for regulating the expression of a desired structural gene, e.g., a mammalian polypeptide. Particularly preferred is the use of these novel promoters to regulate gene expression in polyploidal yeast such as diploidal P. pastoris produced by mating or spheroplast fusion.Type: ApplicationFiled: July 3, 2014Publication date: December 25, 2014Inventors: James M. CREGG, Ilya I. TOLSTORUKOV
-
Publication number: 20140377282Abstract: The present invention provides anti-KDR monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of a variety of cancers, rheumatoid arthritis, diabetic retinopathy and other diseases associated with aberrant VEGF or KDR expression and/or activity.Type: ApplicationFiled: November 1, 2012Publication date: December 25, 2014Applicant: APEXIGEN, INC.Inventors: Yaohuang Ke, Sum Wai Pierre Lee, Yongke Zhang, Guo-Liang Yu, Weimin Zhu
-
Publication number: 20140377845Abstract: A method of producing isoprene is disclosed. In one embodiment, the method comprises the steps of obtaining a host transgenic microorganism and observing the production of isoprene by the microorganism. In another embodiment, the invention is a transgenic host microorganism for producing isoprene.Type: ApplicationFiled: August 28, 2014Publication date: December 25, 2014Inventors: Eric L. Singsaas, Amy Wiberley
-
Publication number: 20140380527Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: November 23, 2012Publication date: December 25, 2014Inventor: Kirk Matthew Schnorr
-
Publication number: 20140377813Abstract: The invention provides a microbial eukaryotic cell capable of utilizing C5 sugars, in particular xylose. Another objective of the invention is to provide an improved protein sequence to enable eukaryotic cells to degrade C5 sugars. The present invention thus provides protein comprising an amino acid sequence having at least 75% identity, preferably 80% identity, most preferably 90% identity, most highly preferably 95% identity to SEQ ID NO. 2 or SEQ ID NO. 8 and having xylose-isomerase activity in a eukaryotic cell.Type: ApplicationFiled: February 7, 2013Publication date: December 25, 2014Inventors: Zdravko Dragovic, Christian Gamauf, Christoph Reisinger, Ulrich Kettling
-
Publication number: 20140377407Abstract: This invention relates to a novel alpha-amylase, a process for its preparation and the use of the amylase. The invention relates to a newly identified polynucleotide sequence from Alicyclobacillus pohliae comprising a gene that encodes the novel alpha-amylase enzyme. The invention features the full length coding sequence of the novel gene as well as the amino acid sequence of the full-length functional protein of the gene. The invention also relates to methods of using these proteins in industrial processes, for example in food industry, such as the baking industry. Also included in the invention are cells transformed with a polynucleotide according to the invention suitable for producing these proteins and cells.Type: ApplicationFiled: January 29, 2013Publication date: December 25, 2014Applicant: DSM IP ASSETS B.V.Inventor: Lucie Parenicova
-
Publication number: 20140377824Abstract: The invention relates to suitable candidate ADH enzymes for production of lower alkyl alcohols including isobutanol. The invention also relates to recombinant host cells that comprise such ADH enzymes and methods for producing lower alkyl alcohols in the same.Type: ApplicationFiled: May 20, 2014Publication date: December 25, 2014Applicant: Butamax Advanced Biofuels LLCInventors: Sriram Satagopan, Daniel P. O'keefe, Janardhan Gude
-
Patent number: 8916361Abstract: The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., “?9-elongase”) and to uses thereof. In particular, ?9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-?-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-?-linolenic acid (DGLA, 20:3n-6) is then catalyzed by ?8-desaturase and ?5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.Type: GrantFiled: November 14, 2007Date of Patent: December 23, 2014Assignee: Abbott LaboratoriesInventors: Tapas Das, Pradip Mukerji, Padmavathy Krishnan, Amanda E. Leonard, Suzette L. Pereira
-
Publication number: 20140370564Abstract: The present disclosure generally relates to microorganisms that comprise one or more polynucleotides coding for enzymes in one or more pathways that catalyze a conversion of a fermentable carbon source to butadiene. Also provided are methods of using the microorganisms in industrial processes including, for use in the production of butadiene and products derived therefrom.Type: ApplicationFiled: December 17, 2012Publication date: December 18, 2014Inventors: Mateus Schreiner Garcez Lopes, Avram Michael Slovic, Iuri Estrada Gouvea, Johana Rincones Perez, Lucas Pedersen Parizzi
-
Publication number: 20140370573Abstract: Isopropanol is produced with good productivity via fermentation processes. Specifically, isopropanol is produced at a high level in a medium by culturing recombinant yeast into which an acetoacetyl CoA synthase gene and a group of genes (isopropanol synthesis-related gene group) encoding a group of enzymes for synthesis of isopropanol from acetoacetyl CoA have been introduced.Type: ApplicationFiled: July 29, 2014Publication date: December 18, 2014Applicant: TOYOTA JIDOSHA KABUSHIKI KAISHAInventors: Masayoshi MURAMATSU, Satoshi YONEDA
-
Publication number: 20140370595Abstract: The present invention provides methods of producing a product or product precursor of a biosynthetic pathway in a genetically modified host cell. The present invention also provides genetically modified host cells comprising nucleic acids encoding a scaffold polypeptide and nucleic acids comprising nucleotide sequences encoding two or more enzymes in a biosynthetic pathway. The present invention further provides nucleic acids comprising nucleotide sequences encoding scaffold polypeptides, for use in a subject method.Type: ApplicationFiled: June 25, 2014Publication date: December 18, 2014Inventors: John E. Dueber, Jay D. Keasling, Gabriel C. Wu, Ghulam Reza K. Malmirchegini
-
Publication number: 20140369940Abstract: Provided are anti-human ?-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human ?-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human ?-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for ?-synuclein targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: June 22, 2012Publication date: December 18, 2014Applicants: University of Zurich, Biogen IDEC International Neuroscience GmbHInventors: Andreas Weihofen, Jan Grimm, Cristoph Hock, Roger Nitsch, Lihe Su, Paul Weinreb
-
MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS
Publication number: 20140371417Abstract: The invention provides non-naturally occurring microbial organisms having a 4-hydroxybutyrate, gamma-butyrolactone, 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-CoA and/or putrescine pathway and being capable of producing 4-hydroxybutyrate, wherein the microbial organism comprises one or more genetic modifications. The invention additionally provides methods of producing 4-hydroxybutyrate, gamma-butyrolactone, 1,4-butanediol, 4-hydroxybutanal, 4-hydroxybutyryl-CoA and/or putrescine or related products using the microbial organisms.Type: ApplicationFiled: April 25, 2014Publication date: December 18, 2014Applicant: Genomatica, Inc.Inventors: Priti PHARKYA, Anthony P. BURGARD, Stephen J. VAN DIEN, Robin E. OSTERHOUT, Mark J. BURK, John D. TRAWICK, Michael P. KUCKINSKAS, Brian STEER -
Publication number: 20140363427Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.Type: ApplicationFiled: June 5, 2014Publication date: December 11, 2014Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Keogh
-
Publication number: 20140363837Abstract: The present invention relates to recombinant heme-containing horseradish peroxidase isoenzymes with improved properties. In particular, the present invention relates to a plant enzyme kit comprising recombinant peroxidase isoenzymes, preferably horseradish peroxidase isoenzymes.Type: ApplicationFiled: October 19, 2012Publication date: December 11, 2014Applicant: Technische Universitaet Graz (Geaz University of TechnologyInventors: Florian Krainer, Laura Naeaetsaari, Anton Glieder, Martin Kulterer, Victoria Reichel
-
Publication number: 20140363858Abstract: Provided herein are methods for producing an ortho-hydroxylated phenylpropanoid. In one embodiment the method includes culturing a microbe that includes HpaBC activity in the presence of a phenylpropanoid substrate. Also provided are genetically engineered microbes engineered to have greater levels of HpaB and/or HpaC than a control microbe.Type: ApplicationFiled: June 10, 2014Publication date: December 11, 2014Inventors: YAJUN YAN, YUHENG LIN
-
Publication number: 20140363864Abstract: A non-naturally occurring microbial organism includes a microbial organism having a 1,4-cyclohexanedimethanol pathway that includes at least one exogenous nucleic acid encoding a 1,4-cyclohexanedimethanol pathway enzyme expressed in a sufficient amount to produce 1,4-cyclohexanedimethanol. A method for producing 1,4-cyclohexanedimethanol includes culturing a non-naturally occurring microbial organism having a 1,4-cyclohexanedimethanol pathway. The pathway includes at least one exogenous nucleic acid encoding a 1,4-cyclohexanedimethanol pathway enzyme expressed in a sufficient amount to produce 1,4-cyclohexanedimethanol, under conditions and for a sufficient period of time to produce 1,4-cyclohexanedimethanol.Type: ApplicationFiled: January 10, 2014Publication date: December 11, 2014Applicant: Genomatica, Inc.Inventors: Priti Pharkya, Mark J. Burk
-
Patent number: 8906666Abstract: The present disclosure provides improved systems for the biological production of aliphatic alcohol compounds. In particular, the present disclosure provides biological systems that show improved resistance to aliphatic alcohol toxicity; in some embodiments, such improved resistance allows for increased levels of aliphatic alcohol production. In one aspect, the present disclosure provides engineered microorganisms that both produce an aliphatic alcohol compound and show resistance to that compound as measured by an ability to grow to predetermined levels in the presence of a given concentration of the compound.Type: GrantFiled: May 22, 2009Date of Patent: December 9, 2014Assignee: Butamax Advanced Biofuels LLCInventors: Keith Alsaker, Daniel Grenfell-Lee, Michael Hudson, Adam Lawrence, Jessica McGrath, David Young
-
Publication number: 20140356478Abstract: Fusion-proteins containing an enzyme, preferably a feed or food enzyme, coupled to a gut surface-binding domain are presented. The fusion-proteins can be used to promote feed utilization in animals. In a particular example, a Fusion enzyme according to the invention comprising a gut-surface-binding polypeptide segment linked to a phytase show an increased resident time in the gut, which leads to an increased amount of time given to the enzyme to catalyse the corresponding reaction which finally leads to improved feed utilisation.Type: ApplicationFiled: June 11, 2012Publication date: December 4, 2014Applicant: NOVOZYMES A/SInventors: Ghislain Schyns, Stephane Duval, Aurelie Brelin
-
Publication number: 20140356960Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.Type: ApplicationFiled: April 25, 2014Publication date: December 4, 2014Inventor: Imre Berger
-
Publication number: 20140356326Abstract: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: December 10, 2013Publication date: December 4, 2014Applicant: Amunix Operating Inc.Inventors: Volker Schellenberger, Willem P. Stemmer, Chia-Wei Wang, Michael D. Scholle, Mikhail Popkov, Nathaniel C. Gordon, Andreas Crameri
-
Publication number: 20140356912Abstract: The present invention relates to the the cell-based production of bacterial nonulosonates and their biosynthetic precursors. Specifically, the present invention provides recombinant cells for the production of pseudaminic acid, legionaminic acid, UDP-2,4-diacetamido-2,4,6-trideoxy-?-L-altropyranose, and UDP-2,4-diacetamido-2,4,6-trideoxy-?-D-glucopyranose. Methods for producing the sugars are also provided.Type: ApplicationFiled: July 28, 2014Publication date: December 4, 2014Inventors: Christopher N. Boddy, Susan M. Logan, Benjamin R. Lundgren, Ian C. Schoenhofen, Dennis M. Whitfield
-
Publication number: 20140356919Abstract: A non-naturally occurring microbial organism has cyclohexanone pathways that include at least one exogenous nucleic acid encoding a cyclohexanone pathway enzyme. A pathway includes a 2-ketocyclohexane-1-carboxyl-CoA hydrolase (acting on C—C bond), a 2-ketocyclohexane-1-carboxylate decarboxylase and an enzyme selected from a 2-ketocyclohexane-1-carboxyl-CoA hydrolase (acting on thioester), a 2-ketocyclohexane-1-carboxyl-CoA transferase, and a 2-ketocyclohexane-1-carboxyl-CoA synthetase.Type: ApplicationFiled: February 4, 2014Publication date: December 4, 2014Inventors: Robin E. Osterhout, Anthony P. Burgard, Mark J. Burk, Priti Pharkya
-
Publication number: 20140356944Abstract: The present disclosure provides engineered transaminase polypeptides having improved properties as compared to naturally occurring transaminases including the ability of converting the substrate, 3?-hydroxyacetophenone to (S)-3-(1-aminoethyl)-phenol in enantiomeric excess and high percentage conversion. Also provided are polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to synthesize (S)-3-(1-aminoethyl)-phenol and related compounds useful in the production of active pharmaceutical ingredients.Type: ApplicationFiled: August 19, 2014Publication date: December 4, 2014Inventors: Fabien Louis Cabirol, Anupam Gohel, Seong Ho Oh, Derek J. Smith, Brian Wong, James J. Lalonde
-
Publication number: 20140356347Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.Type: ApplicationFiled: September 21, 2012Publication date: December 4, 2014Inventors: Stefan Barth, Sonja Schiffer, Grit Hehmann-Titt
-
Publication number: 20140357521Abstract: The disclosure relates cells or cellular systems that express both a membrane protein and a binding domain directed to the membrane protein. Also, methods are provided that use such cells or cellular systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.Type: ApplicationFiled: January 21, 2013Publication date: December 4, 2014Inventors: Jan Steyaert, Nico Callewaert, Toon Laeremans, Els Pardon, Kristof Vandewalle, Katrien Claes
-
Publication number: 20140348817Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
-
Publication number: 20140349395Abstract: The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases.Type: ApplicationFiled: June 5, 2014Publication date: November 27, 2014Applicant: Apexigen, Inc.Inventors: Yongke ZHANG, Guo-Liang YU, Weimin ZHU
-
Publication number: 20140349376Abstract: The present disclosure provides novel beta-alanine/alpha ketoglutarate aminotransferase nucleic acid and protein sequences having increased biological activity. Also provided are cells containing such enzymes, as well as methods of their use, for example to produce malonyl semialdehyde and downstream products thereof, such as 3-hydroxypropionic acid and derivatives thereof.Type: ApplicationFiled: September 12, 2011Publication date: November 27, 2014Inventors: Holly Jean Jessen, Hans H. Liao, Steven John Gort, Olga V. Selifonova
-
Publication number: 20140349342Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.Type: ApplicationFiled: April 23, 2014Publication date: November 27, 2014Applicant: Ablynx N.V.Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
-
Publication number: 20140349372Abstract: The present invention relates to lipase variants and methods of obtaining them. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.Type: ApplicationFiled: January 25, 2013Publication date: November 27, 2014Applicant: Novozymes A/SInventors: Luise Erlandsen, Carsten Hoerslev Hansen, Jesper Vind, Allan Svendsen, Carsten Peter Sonksen
-
Publication number: 20140350223Abstract: Recombinant P. pastoris producing natural sweet proteins and methods for engineering these recombinant yeast are described. Methods for enhancing foreign protein production in yeast fermentation and improved methods for purification of foreign proteins produced in yeast fermentation are presented.Type: ApplicationFiled: April 17, 2014Publication date: November 27, 2014Applicant: Tate & Lyle Technology LimitedInventors: Alfred Carlson, Richard W. Armentrout, Timothy Peter Ellis
-
Publication number: 20140349349Abstract: The present invention is related to recombinant host cells comprising: (i) at least one deletion, mutation, and/or substitution in an endogenous gene encoding a polypeptide that converts pyruvate to acetaldehyde, acetyl-phosphate, or acetyl-CoA; and (ii) a heterologous polynucleotide encoding a polypeptide having phosphoketolase activity. The present invention is also related to recombinant host cells further comprising (iii) a heterologous polynucleotide encoding a polypeptide having phosphotransacetylase activity.Type: ApplicationFiled: July 18, 2014Publication date: November 27, 2014Inventors: MICHAEL DAUNER, Lori Ann Maggio-Hall, Jean-Francois Tomb
-
Patent number: 8895287Abstract: A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.Type: GrantFiled: February 21, 2006Date of Patent: November 25, 2014Assignee: Evolva SAInventors: Michael Katz, Hans Peter Smits, Jochen Förster, Jens Bredal Nielsen
-
Publication number: 20140342431Abstract: Compositions and methods relating to variant alpha-amylases are described.Type: ApplicationFiled: December 18, 2012Publication date: November 20, 2014Applicant: Danisco US INC.Inventors: Luis Gustavo Cascao-Pereira, Marc Kolkman
-
Publication number: 20140341892Abstract: The invention relates to anti-?2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of ?2 integrin and inhibit the interaction of ?2?1 integrin with collagen. Also disclosed are therapeutic uses of anti-?2 integrin antibodies in treating ?2?1-mediated disorders, including anti-?2 integrin antibodies that bind to ?2 integrin without activating platelets.Type: ApplicationFiled: May 19, 2014Publication date: November 20, 2014Applicant: GLENMARK PHARMACEUTICALS S.A.Inventors: Elias LAZARIDES, Catherine Woods, Mark Bernard
-
Publication number: 20140341910Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.Type: ApplicationFiled: November 26, 2013Publication date: November 20, 2014Applicant: GENZYME CORPORATIONInventors: Bruce L. Roberts, Srinivas Shankara, William Harold Brondyk, William M. Siders